Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Beijing Tri Prime Gene Pharmaceutical Co Receivables Turnover Related Terms
Beijing Tri Prime Gene Pharmaceutical Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co Receivables Turnover Chart
Beijing Tri Prime Gene Pharmaceutical Co Annual Data
BJSE:920344 vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, Beijing Tri Prime Gene Pharmaceutical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tri Prime Gene Pharmaceutical Co Receivables Turnover vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) has a Receivables Turnover of 0.92 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. According to the industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #492 out of 849 companies in the Biotechnology industry, placing it in the top 58%.
Is Beijing Tri Prime Gene Pharmaceutical Co's Receivables Turnover too high?
Beijing Tri Prime Gene Pharmaceutical Co's current Receivables Turnover is 0.92. The Biotechnology industry median Receivables Turnover is 5.28. Beijing Tri Prime Gene Pharmaceutical Co's value of 0.92 is 82.6% below this industry median. Based on the distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #492 out of 849 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Tri Prime Gene Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tri Prime Gene Pharmaceutical Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #492 out of 849 companies for Receivables Turnover. This places Beijing Tri Prime Gene Pharmaceutical Co in the lower half of its industry. The industry median Receivables Turnover is 5.28. Beijing Tri Prime Gene Pharmaceutical Co's value of 0.92 is 82.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tri Prime Gene Pharmaceutical Co's current Receivables Turnover of 0.92 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tri Prime Gene Pharmaceutical Co's current Receivables Turnover is 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tri Prime Gene Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥26.28, compared to a current price of ¥21.30 — trading 18.9% below its estimated fair value. The current Receivables Turnover is 0.92 and 82.6% below the Biotechnology industry median of 5.28. Beijing Tri Prime Gene Pharmaceutical Co's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344), the current Receivables Turnover is 0.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥21.30 is trading 18.9% below its estimated GF Value™ of ¥26.28.
GuruFocus considers Beijing Tri Prime Gene Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920344:
Receivables Turnover: 0.92
GF Value™: ¥26.28 vs. price of ¥21.30 (18.9% below fair value)
Industry Position: 82.6% below the Biotechnology median (#492 of 849)
No single metric tells the full story. See the BJSE:920344 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products, including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and is engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, and Yundexol Water Injection.
85GF Score
Get the complete analysis for BJSE:920344
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920344 has been successfully added to your 
